Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer

Andrea Dalbeni, Chiara Ciccarese, Michele Bevilacqua, Marco Benati, Cristian Caimmi, Luca Cerrito, Federico Famà, Roberto Iacovelli, Anna Mantovani, Francesco Massari Alessandra Meneguzzi, Pietro Minuz, Martina Montagnana, Giovanni Orsolini, Maurizio Rossini, Giampaolo Tortora, Ombretta Viapiana, Cristiano Fava

Research output: Contribution to journalArticle

Abstract

Adverse cardiovascular effects, including hypertension, were described in patients with different cancers treated with tyrosine kinase inhibitors (TKI). The mechanism of TKI-related hypertension is still debated. The aim of this work was to study the effects of TKI on blood pressure (BP), searching for a relationship with possible causative factors in patients with metastatic renal cell carcinoma. We included 29 patients in a prospective, observational study; 22 were treated with a first-line drug (sunitinib), while seven participated in the second-line treatment (axitinib or cabozantinib). Patients were investigated at the beginning of antiangiogenic therapy (T0) and at one (T1), three (T2), and six months (T3) after treatment. Patients were evaluated by office blood pressure (BP) and ultrasonography to measure flow-mediated dilatation (FMD), and carotid artery distensibility (cDC) by echocardiography and nailfold capillaroscopy. Plasma endothelin-1 (p-ET-1), urine nitrates, and proteins were also measured. At T1, systolic BP, along with U proteins and p-ET-1, increased significantly. In patients with a clinically significant increase in BP (defined as either the need for an antihypertensive drug or systolic blood pressure (SBP) T1⁻T0 ≥10 and/or SBP ≥140 mmHg and/or diastolic blood pressure (DBP) T1⁻T0 ≥5 and/or DBP ≥90 mmHg), the urine nitrate concentration was lower at T0, whereas there were no differences in the p-ET-1 and U proteins. Seventeen participants showed changes in the capillaroscopic pattern at T1 with no association with BP increases. There were no differences in the FMD, cDC, and echocardiographic parameters. Our findings are consistent with those of previous studies about BP increases by TKI, and suggest a role of nitric oxide in BP maintenance in this population.

Original languageEnglish
JournalCancers
Volume11
Issue number1
DOIs
Publication statusPublished - Dec 28 2018

Fingerprint

Kidney Neoplasms
Microcirculation
Blood Pressure
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Endothelin-1
Nitrates
Dilatation
Microscopic Angioscopy
Urine
Hypertension
Carotid Arteries
Renal Cell Carcinoma
Antihypertensive Agents

Cite this

Dalbeni, A., Ciccarese, C., Bevilacqua, M., Benati, M., Caimmi, C., Cerrito, L., ... Fava, C. (2018). Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. Cancers, 11(1). https://doi.org/10.3390/cancers11010030

Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. / Dalbeni, Andrea; Ciccarese, Chiara; Bevilacqua, Michele; Benati, Marco; Caimmi, Cristian; Cerrito, Luca; Famà, Federico; Iacovelli, Roberto; Mantovani, Anna; Meneguzzi, Francesco Massari Alessandra; Minuz, Pietro; Montagnana, Martina; Orsolini, Giovanni; Rossini, Maurizio; Tortora, Giampaolo; Viapiana, Ombretta; Fava, Cristiano.

In: Cancers, Vol. 11, No. 1, 28.12.2018.

Research output: Contribution to journalArticle

Dalbeni, A, Ciccarese, C, Bevilacqua, M, Benati, M, Caimmi, C, Cerrito, L, Famà, F, Iacovelli, R, Mantovani, A, Meneguzzi, FMA, Minuz, P, Montagnana, M, Orsolini, G, Rossini, M, Tortora, G, Viapiana, O & Fava, C 2018, 'Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer', Cancers, vol. 11, no. 1. https://doi.org/10.3390/cancers11010030
Dalbeni, Andrea ; Ciccarese, Chiara ; Bevilacqua, Michele ; Benati, Marco ; Caimmi, Cristian ; Cerrito, Luca ; Famà, Federico ; Iacovelli, Roberto ; Mantovani, Anna ; Meneguzzi, Francesco Massari Alessandra ; Minuz, Pietro ; Montagnana, Martina ; Orsolini, Giovanni ; Rossini, Maurizio ; Tortora, Giampaolo ; Viapiana, Ombretta ; Fava, Cristiano. / Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. In: Cancers. 2018 ; Vol. 11, No. 1.
@article{c4c90f6f5c554523a18fd6d2d1890ee2,
title = "Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer",
abstract = "Adverse cardiovascular effects, including hypertension, were described in patients with different cancers treated with tyrosine kinase inhibitors (TKI). The mechanism of TKI-related hypertension is still debated. The aim of this work was to study the effects of TKI on blood pressure (BP), searching for a relationship with possible causative factors in patients with metastatic renal cell carcinoma. We included 29 patients in a prospective, observational study; 22 were treated with a first-line drug (sunitinib), while seven participated in the second-line treatment (axitinib or cabozantinib). Patients were investigated at the beginning of antiangiogenic therapy (T0) and at one (T1), three (T2), and six months (T3) after treatment. Patients were evaluated by office blood pressure (BP) and ultrasonography to measure flow-mediated dilatation (FMD), and carotid artery distensibility (cDC) by echocardiography and nailfold capillaroscopy. Plasma endothelin-1 (p-ET-1), urine nitrates, and proteins were also measured. At T1, systolic BP, along with U proteins and p-ET-1, increased significantly. In patients with a clinically significant increase in BP (defined as either the need for an antihypertensive drug or systolic blood pressure (SBP) T1⁻T0 ≥10 and/or SBP ≥140 mmHg and/or diastolic blood pressure (DBP) T1⁻T0 ≥5 and/or DBP ≥90 mmHg), the urine nitrate concentration was lower at T0, whereas there were no differences in the p-ET-1 and U proteins. Seventeen participants showed changes in the capillaroscopic pattern at T1 with no association with BP increases. There were no differences in the FMD, cDC, and echocardiographic parameters. Our findings are consistent with those of previous studies about BP increases by TKI, and suggest a role of nitric oxide in BP maintenance in this population.",
author = "Andrea Dalbeni and Chiara Ciccarese and Michele Bevilacqua and Marco Benati and Cristian Caimmi and Luca Cerrito and Federico Fam{\`a} and Roberto Iacovelli and Anna Mantovani and Meneguzzi, {Francesco Massari Alessandra} and Pietro Minuz and Martina Montagnana and Giovanni Orsolini and Maurizio Rossini and Giampaolo Tortora and Ombretta Viapiana and Cristiano Fava",
year = "2018",
month = "12",
day = "28",
doi = "10.3390/cancers11010030",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer

AU - Dalbeni, Andrea

AU - Ciccarese, Chiara

AU - Bevilacqua, Michele

AU - Benati, Marco

AU - Caimmi, Cristian

AU - Cerrito, Luca

AU - Famà, Federico

AU - Iacovelli, Roberto

AU - Mantovani, Anna

AU - Meneguzzi, Francesco Massari Alessandra

AU - Minuz, Pietro

AU - Montagnana, Martina

AU - Orsolini, Giovanni

AU - Rossini, Maurizio

AU - Tortora, Giampaolo

AU - Viapiana, Ombretta

AU - Fava, Cristiano

PY - 2018/12/28

Y1 - 2018/12/28

N2 - Adverse cardiovascular effects, including hypertension, were described in patients with different cancers treated with tyrosine kinase inhibitors (TKI). The mechanism of TKI-related hypertension is still debated. The aim of this work was to study the effects of TKI on blood pressure (BP), searching for a relationship with possible causative factors in patients with metastatic renal cell carcinoma. We included 29 patients in a prospective, observational study; 22 were treated with a first-line drug (sunitinib), while seven participated in the second-line treatment (axitinib or cabozantinib). Patients were investigated at the beginning of antiangiogenic therapy (T0) and at one (T1), three (T2), and six months (T3) after treatment. Patients were evaluated by office blood pressure (BP) and ultrasonography to measure flow-mediated dilatation (FMD), and carotid artery distensibility (cDC) by echocardiography and nailfold capillaroscopy. Plasma endothelin-1 (p-ET-1), urine nitrates, and proteins were also measured. At T1, systolic BP, along with U proteins and p-ET-1, increased significantly. In patients with a clinically significant increase in BP (defined as either the need for an antihypertensive drug or systolic blood pressure (SBP) T1⁻T0 ≥10 and/or SBP ≥140 mmHg and/or diastolic blood pressure (DBP) T1⁻T0 ≥5 and/or DBP ≥90 mmHg), the urine nitrate concentration was lower at T0, whereas there were no differences in the p-ET-1 and U proteins. Seventeen participants showed changes in the capillaroscopic pattern at T1 with no association with BP increases. There were no differences in the FMD, cDC, and echocardiographic parameters. Our findings are consistent with those of previous studies about BP increases by TKI, and suggest a role of nitric oxide in BP maintenance in this population.

AB - Adverse cardiovascular effects, including hypertension, were described in patients with different cancers treated with tyrosine kinase inhibitors (TKI). The mechanism of TKI-related hypertension is still debated. The aim of this work was to study the effects of TKI on blood pressure (BP), searching for a relationship with possible causative factors in patients with metastatic renal cell carcinoma. We included 29 patients in a prospective, observational study; 22 were treated with a first-line drug (sunitinib), while seven participated in the second-line treatment (axitinib or cabozantinib). Patients were investigated at the beginning of antiangiogenic therapy (T0) and at one (T1), three (T2), and six months (T3) after treatment. Patients were evaluated by office blood pressure (BP) and ultrasonography to measure flow-mediated dilatation (FMD), and carotid artery distensibility (cDC) by echocardiography and nailfold capillaroscopy. Plasma endothelin-1 (p-ET-1), urine nitrates, and proteins were also measured. At T1, systolic BP, along with U proteins and p-ET-1, increased significantly. In patients with a clinically significant increase in BP (defined as either the need for an antihypertensive drug or systolic blood pressure (SBP) T1⁻T0 ≥10 and/or SBP ≥140 mmHg and/or diastolic blood pressure (DBP) T1⁻T0 ≥5 and/or DBP ≥90 mmHg), the urine nitrate concentration was lower at T0, whereas there were no differences in the p-ET-1 and U proteins. Seventeen participants showed changes in the capillaroscopic pattern at T1 with no association with BP increases. There were no differences in the FMD, cDC, and echocardiographic parameters. Our findings are consistent with those of previous studies about BP increases by TKI, and suggest a role of nitric oxide in BP maintenance in this population.

U2 - 10.3390/cancers11010030

DO - 10.3390/cancers11010030

M3 - Article

C2 - 30597890

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

ER -